BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25098685)

  • 21. [Study on combined gene therapy for malignant gliomas transfected with antisense hTERT/PTEN in vitro and in vivo].
    You YP; Fu Z; Zhao P; Wang CZ; Liu N; Lu AL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):605-9. PubMed ID: 17160935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of human telomerase reverse transcriptase in hep-2 cells using short hairpin RNA expression vectors.
    Chen SM; Tao ZZ; Hua QQ; Liu D; Chi HM; Cai Q
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):200-5. PubMed ID: 16490880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y; Shen K; Yu JR
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of antisense human telomerase reverse-transcript protein subunit (hTERT) gene on biological characteristics of hepatoblastoma cell line in vitro].
    Liu L; Li CR; Sun LB; Wang GB; Wang B
    Zhonghua Er Ke Za Zhi; 2004 Jul; 42(7):481-5. PubMed ID: 15324561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combination of antisense human telomerase RNA and antisense human telomerase catalytic subunit inhibits cervical cancer Hela cells growth].
    Lei LX; Chen ZD
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):42-6. PubMed ID: 15774092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mad1 suppresses bladder cancer cell proliferation by inhibiting human telomerase reverse transcriptase transcription and telomerase activity.
    Zou L; Zhang P; Luo C; Tu Z
    Urology; 2006 Jun; 67(6):1335-40. PubMed ID: 16765199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhibitory effect of antisense human telomerase reverse transcriptase(hTERT) on telomerase activity of human pulmonary giant cell carcinoma cell line(PLA-801D)].
    Ma XB; Han WD; Hao HJ; Li Q; Xu ZM; Lu XC; Zhao YL
    Ai Zheng; 2003 Sep; 22(9):932-7. PubMed ID: 12969524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors.
    Liu M; Wang RF; Zhang CL; Yan P; Yu MM; Di LJ; Liu HJ; Guo FQ
    J Nucl Med; 2007 Dec; 48(12):2028-36. PubMed ID: 18006621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antisense human telomerase reverse transcriptase inhibits leukemia cell proliferation in vitro].
    Sun LB; Li CR; Wen JM; Wang GB; Zhang M; Yang J; Li RX
    Di Yi Jun Yi Da Xue Xue Bao; 2004 May; 24(5):521-4. PubMed ID: 15151822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement.
    Won YS; Jeong JS; Kim SJ; Ju MH; Lee SW
    Cancer Lett; 2015 Jan; 356(2 Pt B):918-28. PubMed ID: 25444904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Inhibition of anti-sense human telomerase reverse transcriptase (hTERT) retroviral vector on lung cancer cells].
    Tian FJ; Wang ZY; Ma JY; Zhao YX; Lu W
    Ai Zheng; 2004 May; 23(5):545-9. PubMed ID: 15142451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells.
    Misawa M; Tauchi T; Sashida G; Nakajima A; Abe K; Ohyashiki JH; Ohyashiki K
    Int J Oncol; 2002 Nov; 21(5):1087-92. PubMed ID: 12370759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and distribution of human telomerase catalytic component, hTERT, in human breast tissues.
    Yano Y; Yoshida K; Osaki A; Toge T; Tahara H; Ide T; Yasui W
    Anticancer Res; 2002; 22(6C):4101-7. PubMed ID: 12553039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. hTERT gene expression levels and telomerase activity in drug resistant MCF-7 cells.
    Sakin V; Eskiocak U; Kars MD; Iseri OD; Gunduz U
    Exp Oncol; 2008 Sep; 30(3):202-5. PubMed ID: 18806742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells.
    Wu ZQ; Guo QL; You QD; Zhao L; Gu HY
    Biol Pharm Bull; 2004 Nov; 27(11):1769-74. PubMed ID: 15516720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.
    Ouchi H; Ishiguro H; Ikeda N; Hori M; Kubota Y; Uemura H
    Int J Urol; 2005 Jan; 12(1):73-80. PubMed ID: 15661057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma.
    He H; Xia HH; Wang JD; Gu Q; Lin MC; Zou B; Lam SK; Chan AO; Yuen MF; Kung HF; Wong BC
    Cancer; 2006 Mar; 106(6):1243-9. PubMed ID: 16444744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Riccardin D, a macrocyclic bisbibenzy, inhibits human breast cancer growth through the suppression of telomerase activity.
    Sun CC; Xu HM; Yuan Y; Gao ZH; Lou HX; Qu XJ
    Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):488-98. PubMed ID: 24836118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of human telomerase reverse transcriptase in vivo and in vitro for retroviral vector-based antisense oligonucleotide therapy in ovarian cancer.
    Qi Z; Mi R
    Cancer Gene Ther; 2016 Jan; 23(1):36-42. PubMed ID: 26742579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant.
    Samy M; Gattolliat CH; Pendino F; Hillion J; Nguyen E; Bombard S; Douc-Rasy S; Bénard J; Ségal-Bendirdjian E
    Mol Cancer Ther; 2012 Nov; 11(11):2384-93. PubMed ID: 22933702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.